Some studies have suggested patients with aggressive tumor types, such as TNBC and HER2-positive (HER2+) tumors, tended to benefit more from NACT due to higher pCR rates, which are associated with improved survival outcomes.9–11. The gene discussed is ERBB2; the disease is neoplasm.